海泰新光(688677.SH)2022年度淨利潤預增54.02%
格隆匯1月29日丨海泰新光(688677.SH)公佈,預計2022年年度實現歸屬於母公司所有者的淨利潤與上年同期(法定披露數據)相比,將增加6359.84萬元,同比增加54.02%左右;歸屬於母公司所有者的扣除非經常性損益的淨利潤與上年同期(法定披露數據)相比,將增加7343.4萬元,同比增加78.12%左右。
報吿期內,公司主營業務突出,公司收入增長帶動利潤增長。得益於新產品的推出以及客户需求的增加,公司醫用內窺鏡產品和光學產品的業務都有較為明顯的增長。另外,2022年美元匯率的變化也在一定程度上帶來了公司利潤的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.